Delayed Endothelial Progenitor Cell Therapy Promotes Bone Defect Repair in a Clinically Relevant Rat Model

Area of Science:

• Orthopaedic Surgery
• Regenerative Medicine
• Biomaterials Science

Background:

• Segmental bone defect repair is a significant clinical challenge.
• Endothelial progenitor cells (EPCs) show potential for acute bone defect healing.
• The efficacy of EPCs for chronic, nonhealing defects remains largely uninvestigated.

Purpose of the Study:

• To investigate the ability of delayed endothelial progenitor cell (EPC) delivery to induce repair of nonhealing bone defects.
• To evaluate EPCs in a clinically relevant animal model simulating delayed treatment.
• To assess the impact of EPCs on bone defect union and mechanical properties.

Main Methods:

• Fischer 344 rat femora with 5 mm segmental defects were used.
• Bone marrow-derived EPCs on a Gelfoam scaffold were applied 3 weeks post-defect creation (delayed treatment).
• Control groups received Gelfoam scaffold alone.

Main Results:

• 100% of EPC-treated defects achieved union at 10 weeks post-treatment.
• Complete union was observed in only 37.5% of control defects.
• EPC treatment significantly increased ultimate torque (p=0.022) and torsional stiffness (p=0.003).
• No significant difference in outcomes between acute and delayed EPC treatments was noted.

Conclusions:

• Endothelial progenitor cells (EPCs) can effectively enhance bone healing in both acute and delayed treatment scenarios.
• Delayed EPC application promotes the repair of chronic, nonhealing bone defects.
• EPC therapy represents a potentially clinically translatable approach for bone regeneration in humans.